- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07794540
Early Versus Delayed Closure of Bladder Exstrophy in Female Patients
Primary Single-Stage Early Versus Delayed Closure of Bladder Exstrophy in Female Patients: A Randomized Controlled Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Eligible phenotypic female neonates who presented with classic bladder exstrophy within the first 48 hours of life and met the prespecified clinical and anaesthetic criteria were enrolled through consecutive sampling. After written consent and baseline assessment, participants were randomized in a 1:1 ratio using a computer-generated sequence with randomly varying block sizes and stratification by centre. Allocation was implemented through sequentially numbered sealed envelopes prepared independently of recruitment.
Participants assigned to early closure underwent primary single-stage repair within 72 hours of birth. Participants assigned to delayed closure underwent the same repair at 6 to 12 weeks of age. Before delayed surgery, the exposed bladder plate was cleaned with sterile saline and covered with a clear non-adherent pad, while hydration and weight gain were monitored. The operation included closure of the bladder and posterior urethra and reconstruction of the lower abdominal wall, pelvic floor, and female external genitalia. Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension. Perioperative care was standardized in both groups.
Participants were assessed on postoperative days 7, 14, and 30. Successful bladder closure on postoperative day 30 required an intact deep bladder and abdominal-wall closure without full-thickness wound dehiscence, urinary fistula, or urinary leakage requiring repeat closure or urinary diversion. Secondary outcomes were wound dehiscence, surgical-site infection, urinary fistula, blood transfusion, reoperation, readmission, hospital stay, and adverse events. The primary analysis followed the intention-to-treat principle.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistan
- Khyber Teaching Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
Accepte les volontaires sains
La description
Inclusion Criteria:
- Phenotypic female neonates presenting with classic bladder exstrophy within the first 48 hours of life
- Met the protocol-defined minimum birth-weight requirement
- Gestational age of at least 34 weeks
- Clinically stable and fit for general anaesthesia
- Written informed consent provided by a parent or legal guardian
Exclusion Criteria:
- Cloacal exstrophy, an exstrophy variant, or isolated epispadias
- Previous bladder or abdominal-wall surgery
- Life-threatening congenital anomaly
- Uncontrolled sepsis
- Coagulopathy
- Cardiorespiratory instability precluding surgery within the assigned window
- Parent or legal guardian unable or unwilling to comply with follow-up
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Early Closure
Participants underwent primary single-stage closure within 72 hours of birth.
|
Primary single-stage closure performed within 72 hours of birth.
The procedure included closure of the bladder and posterior urethra and reconstruction of the lower abdominal wall, pelvic floor, and female external genitalia during one anaesthetic.
Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension.
|
|
Comparateur actif: Delayed Closure
Participants underwent primary single-stage closure at 6 to 12 weeks of age.
|
Primary single-stage closure performed at 6 to 12 weeks of age using the same operative checklist and repair.
Before surgery, the exposed bladder plate was cleaned with sterile saline and covered with a clear non-adherent pad, with monitoring of hydration and weight gain.
Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Successful Bladder Closure at Postoperative Day 30
Délai: Postoperative day 30
|
Number and percentage of participants with an intact deep bladder and abdominal-wall closure without full-thickness abdominal wound dehiscence, urinary fistula, or urinary leakage requiring repeat closure or urinary diversion on or before postoperative day 30.
|
Postoperative day 30
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Wound Dehiscence Within 30 Days
Délai: From surgery through postoperative day 30
|
Number and percentage of participants with partial or complete, superficial or deep disruption of the operative wound within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Surgical-Site Infection Within 30 Days
Délai: From surgery through postoperative day 30
|
Number and percentage of participants with inflammatory signs at the operative site, with or without purulent discharge or positive culture, requiring antibiotic or surgical treatment within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Urinary Fistula Within 30 Days
Délai: From surgery through postoperative day 30
|
Number and percentage of participants with continuous urinary leakage from the wound or another site after surgery, confirmed clinically or by imaging and requiring continued drainage or intervention.
|
From surgery through postoperative day 30
|
|
Blood Transfusion
Délai: From the start of surgery through hospital discharge, up to 30 days after surgery
|
Number and percentage of participants who received a blood transfusion during the operative or perioperative period.
|
From the start of surgery through hospital discharge, up to 30 days after surgery
|
|
Reoperation Within 30 Days
Délai: From surgery through postoperative day 30
|
Number and percentage of participants who underwent a repeat surgical procedure related to the primary closure within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Readmission Within 30 Days
Délai: From discharge through postoperative day 30
|
Number and percentage of participants readmitted to hospital within 30 days after surgery.
|
From discharge through postoperative day 30
|
|
Hospital Stay
Délai: From surgery to hospital discharge, up to 30 days after surgery
|
Duration of the index postoperative hospital stay, measured in days from surgery to discharge.
|
From surgery to hospital discharge, up to 30 days after surgery
|
|
Any Adverse Event Within 30 Days
Délai: From surgery through postoperative day 30
|
Number and percentage of participants with at least one recorded adverse event within 30 days after surgery.
|
From surgery through postoperative day 30
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Anomalies congénitales
- Maladies de la vessie urinaire
- Anomalies urogénitales
- Maladies et anomalies congénitales, héréditaires et néonatales
- Exstrophie de la vessie
Autres numéros d'identification d'étude
- KTH-BE-RCT-2021-2026
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .